Welcomer to the mass market era of GLP-1
Source: Tom Ellis, Linkedin If 2025 was the year GLP-1s grabbed the headlines, 2026 is the year they go mass market. The Economist has already flagged "Ozempic, but better" as a top 10 trend for the year. At Brand Genetics we believe 2026 is the tipping point where this evolves from a Western luxury into a global commodity. Here are five reasons why 2026 changes the rules of the game: 1. The Friction is Vanishing Barriers to entry are collapsing. We are moving from needles to pills, shifting GLP-1 from a "medical procedure" to a "daily vitamin". Crucially, patents are expiring in key markets like Brazil, China and India. With generics set to slash prices by up to 80%, access will democratise overnight 2. The "Godzilla" Effect The next generation of drugs are terrifyingly effective: Eli Lilly’s so called "Godzilla" drug (retatrutide) is showing ~24% weight loss in trials. But the real shift is quality: new treatments are designed t...